Activity of selected aromatic amino acids in biological systems

Acta Biochimica Polonica

Volumn 58, Issue 4, 2011, Pages 461-466

  Krzyściak, Wirginia ^a  

^a JAGIELLONIAN UNIVERSITY   (Poland)

Author keywords

Kynurenic acid; Reactive oxygen species; Tyrosine

Indexed keywords

EID: 84860476981     PISSN: 0001527X     EISSN: 1734154X     Source Type: Journal    
DOI: 10.18388/abp.2011_2211     Document Type: Review

References (28)

1. Banach M, Gurdziel E, Jȩdrych M, Borowicz KK (2011) Melatonin in experimental seizures and epilepsy. Pharmacol Rep 63: 1-11.
2. Bonda DJ, Mailankot M, Stone JG, Garrett MR, Staniszewska M, Castellani RJ, Siedlak SL, Zhu X, Lee H, Nagaraj RH, Smith MA (2010) Indoleamine 2,3-dioxygenase and 3OH-kynurenine modifications are found in the neuropathology of Alzheimer disease. Redox Rep 15: 161-168.
3. Brandacher G, Hoeller E, Fuchs D, Weiss HG (2007) Chronic immune activation underlies morbid obesity: Is IDO a key player? Current Drug Metabolism 8: 289-295
4. Buczko P, Cylwik D, Stokowska W (2005) Metabolism of tryptophan via kinurenin patchway in the saliva. Postȩpy Hig Med Dosw 59: 283-289 (in Polish).
5. Buczko P, Stokowska W, Górska M, Kucharewicz I, Pawlak D, Buczko W (2006) Tryptophan Metabolites via kynurenine pathway in saliva of diabetic patients. Dent Med Probl 43: 21-25.
6. Chung KT, Gadupudi GS (2011) Possible roles of excess tryptophan metabolites in cancer. Environ Mol Mutagen 52: 81-104.
7. Fung MM, Viveros OH, O'Connor DT (2008) Diseases of the adrenal medulla. Acta Physiologica 192: 325-335.
8. Garnier JP, Letellier S, Cassinat B, Lebbé C, Kerob D, Baccard M, Morel P, Basset-Seguin N, Dubertret L, Bousquet B, Stoitchkov K, Le Bricon T (2007) Eur J Cancer 43: 816-21
9. Hadjiconstantinou M, Neff NH (2008) Enhancing aromatic L-amino acid decarboxylase activity: implications for l-DOPA treatment in Parkinson's disease. CNS Neurosci Ther 14: 340-51.
10. Källberg E, Wikström P, Bergh A, Ivars F, Leanderson T (2010) Indoleamine 2,3-Dioxygenase (IDO) Activity influence tumor growth in the TRAMP prostate cancer model. The Prostate 70: 1461-1470.
11. Koenig P, Nagl C, Neurauter G, Schenech H, Brandacher G, Fuchs D (2010) Enhanced degradation of tryptophan in patients on hemodialysis. Clin Nephrol 74: 465-70.
12. Kopple JD (2007) Phenylalanine and tyrosine metabolism in chronic kidney failure. The J Nutr 137: 1586-1590.
13. Maes M, Leonard BE, Myint AM, Kubera M, Verkerk R (2011) The new '5-HT' hypothesis of depression: Cell-mediated immune activaction induces indoleamine 2,3-dioxygenaze, which leads to lower plasma tryptophan and an increased synthesis of detrimental tryptophan catabolites (TRYCATs), both of which contribute to the onset of depression. Prog Neuropsychopharmacol Biol Psychiatry 35: 702-21.
14. Mendelsohn D, Riedel WJ, Sambeth A (2009) Effects of acute tryptophan depletion on memory, attention and executive functions: A systematic review. Neur Biobehav Rev 33: 926-952.
15. Merens W, Booij L, Haffmans PJ, Does AJ (2008) The effects of experimentally lowered serotonin function on emotional information processing and memory in remitted depressed patients. J Psychopharmacol 22: 653-662.
16. Nowak A, Libudzisz Z (2008) Carcinogenic activity of intestinal microorganisms. Nauka. Technologia. Jakość 6: 25-39 (in Polish).
17. Oxenkrug GF (2010) Metabolic syndrome, age-associated neuroendocrine disorders, and dysregulation of tryptophan-kynurenine metabolism. Ann N Y Acad Sci USA 11: 1-14.
18. Pawlak K, Domaniewski T, Myśliwiec M, Pawlak D (2009) The kynurenines are associated with oxidation stress, inflammation and the prevalence of cardiovascular disease in patients with end-stage renal disease. Atherosclerosis 204: 309-314.
19. Pawlak K, Domaniewski T, Myśliwiec M, Pawlak D (2009) Kynurenines and oxidative status are independently associated with thrombomodulin and von Willebrand factor levels in patient with endstage renal disease. Thrombosis Res 124: 452-457.
20. Pawlak K, Myśliwiec M, Pawlak D (2010) Haemostatic system, biochemical profiles, kynurenines and the prevalence of cardiovascular disease in peritoneally dialized patients. Thrombosis Res 125: 40-45.
21. Rossi F, Garavaglia S, Montalbano V, Walsh MA, Rizzi M (2008) Crystal structure of human kynurenine aminotransferase ii, a drug target for treatment of schizofrenia. J Biol Chem 283: 3559-3566.
22. Rowland LP (2005), Primary lateral sclerosis, hereditary spastic paraplegia, and mutations in the alsin gene: historical background for the first International Conference. Amyotroph Lateral Scler Other Motor Neuron Disord 6: 67-76.
23. Sasaki N, Egashira Y, Sanada H (2009) Production of l-tryptophan-derived catabolites in hepatocytes from streptozocin-induced diabetic rats. Eur J Nutr 48: 145-153.
24. Stone TW, Mackay GM, Forrest CM, Clark CJ, Darlington LG (2003) Tryptophan metabolites and brain disorders. Clin Chem Lab Med 41: 852-859.
25. Suzuki Y, Suda T, Furuhashi K, Suzuki M, Fujie M, Hahimoto D, Nakamura Y, Inui N, Nakamura H, Chida K (2010) Increased serum kynurenine/tryptophan ratio correlates with disease progression in lung cancer. Lung Cancer 67: 361-365.
26. Tedroff JM (1999) Functional consequences of dopaminergic degeneration in Parkinson's disease. Adv Neurol 80: 67-70.
27. Thomas DM, Angoa Pérez M, Francescutti-Verbeem DM, Shah MM, Kuhn DM (2010) The role of endogenous serotonin in methamphetamine-induced neurotoxicity to dopamine nerve endings of the striatum. J Neurochem 115: 595-605.
28. Thomas SR, Stocker R (1999) Redox reactions related to indoleamine 2,3-dioxygenase and tryptophan metabolism along the kynurenine pathway. Redox Rep 4: 199-220.